American Academy of Dermatology

Philip Mease, MD, PhD | Credit: National Psoriasis Foundation

Deucravacitinib Improves PsA Symptoms and Quality of Life in POETYK PsA-2

March 9th 2025

Data from the POETYK PsA-2 trial examining deucravacitinib were presented at the 2025 American Academy of Dermatology annual meeting.

Guselkumab May Provide Benefit for Psoriatic Arthritis Across Multiple Domains

ByJonathan Alicea

April 24th 2021

A post-hoc analysis shows that the human monoclonal antibody was linked to sustained improvements according to different disease measurements through week 52.